The role of interleukin 1 in the development of human diseases

The role of interleukin 1 in the development of human diseases

Show other versions (1)

Human immuno-inflammatory diseases (IID), depending on the predominant mechanisms of immune activation, are divided into two main categories: autoimmune and autoinflammatory. It is assumed that hyperproduction of "proinflammatory" and immunoregulatory cytokine-interleukin 1 (IL 1) largely...

Full description

Bibliographic Details
Main Author:	E. L. Nasonov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2019-04-01
Series:	Научно-практическая ревматология
Subjects:	immunoinflammatory diseases interleukin 1 inflammasome canakinumab
Online Access:	https://rsp.mediar-press.net/rsp/article/view/2686

Similar Items

ROLE OF INTERLEUKIN 1 IN THE DEVELOPMENT OF HUMAN DISEASES
by: E. L. Nasonov, et al.
Published: (2016-03-01)

Role of interleukin 1 in the development of atherosclerosis
by: E. L. Nasonov, et al.
Published: (2019-04-01)

Problems of immunopathology and prospects for pharmacotherapy of idiopathic recurrent pericarditis: Using an interleukin 1 inhibitor (Anakinra)
by: E. L. Nasonov, et al.
Published: (2023-03-01)

The Role of Interleukin 1β in the Pathogenesis of Lung Cancer
by: Edward B. Garon, MD, et al.
Published: (2020-03-01)

Therapy with canakinumab for adult-onset still's disease
by: E. L. Nasonov
Published: (2019-04-01)

Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
by: Athina Dimosiari, et al.
Published: (2023-02-01)

Therapy with canakinumab for gout
by: M. S. Eliseev, et al.
Published: (2019-04-01)

Adult Still's disease: New horizons
by: E. L. Nasonov, et al.
Published: (2021-12-01)

Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children
by: Sara Signa, et al.
Published: (2020-06-01)

Successful treatment of periodic disease and secondary AA amyloidosis in a colchicine-resistant patient
by: V. V. Rameev, et al.
Published: (2018-01-01)

Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study
by: Serena Colafrancesco, et al.
Published: (2017-06-01)

Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts
by: Serena Colafrancesco, et al.
Published: (2019-12-01)

The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review
by: Véronique Hentgen, et al.
Published: (2020-05-01)

IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis
by: N. Vergis, et al.
Published: (2021-11-01)

A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study
by: Antonio Vitale, et al.
Published: (2016-10-01)

ANTI-INFLAMMATORY THERAPY FOR ATHEROSCLEROSIS: CONTRIBUTION TO AND LESSONS OF RHEUMATOLOGY
by: E. L. Nasonov, et al.
Published: (2017-10-01)

Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
by: Paola Galozzi, et al.
Published: (2018-09-01)

EXPERIENCE OF ADMINISTRATION OF CANAKINUMAB, AN INTERLEUKIN 1β INHIBITOR, IN A PATIENT WITH CHRONIC TOPHACACEOUS GOUT
by: Maksim Sergeyevna Eliseev, et al.
Published: (2014-03-01)

Janus kinase inhibitors in immunoinflammatory rheumatic diseases
by: Evgeny L. Nasonov
Published: (2022-06-01)

Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review
by: Naomi Schlesinger, et al.
Published: (2023-07-01)

In vitro effects of interleukin (IL)-1 beta inhibition on the epithelial-to-mesenchymal transition (EMT) of renal tubular and hepatic stellate cells
by: Valentina Masola, et al.
Published: (2019-01-01)

Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
by: Shao-Huan Lan, et al.
Published: (2023-12-01)

Interleukin-18 and interleukin-18 Binding Protein
by: Charles eDinarello, et al.
Published: (2013-10-01)

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience
by: Lingzhi Qiu, et al.
Published: (2024-03-01)

The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist)
by: E. L. Nasonov, et al.
Published: (2022-07-01)

IMMUNOINFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TYPE I INTERFERON: NEW EVIDENCE
by: E. L. Nasonov, et al.
Published: (2019-09-01)

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab
by: Khetam Ghannam, et al.
Published: (2021-09-01)

Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease
by: Eliana Shaul, et al.
Published: (2022-09-01)

Schnitzler syndrome: A review of literature, the authors’ observation, and experience with the interleukin-1 inhibitor canakinumab
by: S O Salugina, et al.
Published: (2017-11-01)

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
by: Jurgen Sota, et al.
Published: (2019-01-01)

A case of Schnitzler’s syndrome without monoclonal gammopathy successfully treated with canakinumab
by: Yuya Fujita, et al.
Published: (2021-03-01)

Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study
by: Ekaterina Alexeeva, et al.
Published: (2023-11-01)

Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry
by: Elke Lainka, et al.
Published: (2021-03-01)

Evaluation of Caspase-1, Interleukin-1β, and Interleukin-18, in the Middle Ear Effusion in Children With Otitis Media With Effusion
by: Shanshan Liu, et al.
Published: (2021-11-01)

Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review
by: E. L. Nasonov, et al.
Published: (2021-12-01)

Interleukin-1 in Febrile Infection-Related Epilepsy Syndrome
by: Joon Won Kang, et al.
Published: (2023-07-01)

Interleukin-6 inhibition in the treatment of autoinflammatory diseases
by: Tomohiro Koga, et al.
Published: (2022-07-01)

Beneficial and detrimental roles of NLRs in carcinogenesis
by: Ann M Janowski, et al.
Published: (2013-11-01)

Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response
by: Antonio Vitale, et al.
Published: (2019-04-01)

Development of the doctrine of auto-inflammatory diseases in the XXI century
by: E. S. Fedorov, et al.
Published: (2019-04-01)